Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

The document encourages attending the 2023 Dermatology Nurses' Association Convention.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Tridax procumbens may help treat diabetes.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.

Baricitinib may not always prevent relapse in alopecia areata.

Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.

Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.